Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23, 10:00-12:10
Advanced Stem Cell Culture Technology Session
Stay tuned
Planners
Shang Xiao: Founder and Chairman of Youyi Bio
Wei Wu: General Manager of Youyi Bio
10:00-10:05 Opening Remarks
Shang Xiao: Founder and Chairman of Youyi Bio
10:05-10:20 Culture of MSC: from 2D to 3D, and beyond
Lianming Liao: Chief Scientific Officer (CSO) of Topcel Bio
10:20-10:35 High-Efficiency Exosome Production Factory Driven by All-Factor Integrated Medium
Ali Mohsin: Vice President of R&D, Youyi Bio
10:35-10:50 Application of Domestic CUR Bioreactor in the CGT Field
Chaodong Li: Chief Scientist of JYSS Bio
10:50-11:30 Panel Discussion: Supply Chain Risks and Challenges in Cell Therapy Under Dual-Track Regulation Following the Implementation of Orders 818 and 828
Ting Zhang (Moderator): CEO of Regend Therapeutics
Yutian Shen: Co-founder and CEO of Cellgenes
Zhiying He: Professor and Executive Director of the Institute for Regenerative Medicine, East Hospital Affiliated to Tongji University
Yonghong Yin: Deputy General Manager of Celliver Bio
Yijie Yang: Co-founder and CEO of HUIXIN LIFETECH
Yueming Wang: Former General Manager of AegleStem® Therapeutic; International Advisor to the Beijing Daxing International Airport Lin-gang Economic Zone
11:30-12:10 Panel Discussion: Compliance and Prospects of MSC (Mesenchymal Stem Cell) Therapy
Wei Wu (Moderator): General Manager of Youyi Bio
Guanghua Yang: Chief Scientist, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Chairman of NucleusGene (Shanghai) Pharmaceutical Technology Co., Ltd.
Wenjun Zhang: Deputy Director, Institute of Hematology, Tongji University; Deputy Director, Cancer Center, Tongji Hospital; Deputy Director, Institute of Hematology, Tongji University School of Medicine
Chencai Liu: Deputy General Manager of Qichuang Research Institute
Ruiting Pan: Managing Director and Head of China, JIF Capital